NeuroPace (NPCE) Preferred Stock Liabilities (2020 - 2021)
NeuroPace's (NPCE) quarterly Preferred Stock Liabilities came in at $141.4 million in Q1 2021, up 92.23% year-on-year from $73.6 million in Q1 2020, and little changed quarter-over-quarter from $141.4 million in Q4 2020.
NeuroPace (NPCE) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
NeuroPace's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $141.4 million for Q1 2021.
- On a quarterly basis, Preferred Stock Liabilities rose 92.23% year-over-year to $141.4 million in Q1 2021; TTM through Mar 2021 was $141.4 million, a 92.23% increase from a year earlier, with the FY2020 full-year figure at $141.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $141.4 million in Q1 2021 per NPCE's latest filing, from $141.4 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $141.4 million in Q3 2020 and bottomed at $73.5 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | NeuroPace | 494.96 Mn | 440.98 Mn | 18.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 141.42 Mn |
| Dec 31, 2020 | 141.42 Mn |
| Sep 30, 2020 | 141.42 Mn |
| Jun 30, 2020 | 73.45 Mn |
| Mar 31, 2020 | 73.57 Mn |